Alivus Life Sciences growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr2 yr
Revenue+5.6%+3.7%
EBITDA+5.0%+4.6%
Net Income+0.8%+6.0%
Total Assets+5.5%+7.4%
Total Equity+9.1%+6.5%
Free Cash Flow+98.4%−21.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,243.00

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+5.6+3.7
EBITDA+5.0+4.6
Net Income+0.8+6.0
Total Assets+5.5+7.4
Total Equity+9.1+6.5
Free Cash Flow+98.4-21.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.